americanpharmaceuticalreviewSeptember 10, 2018
Tag: Olaparib , I-SPY 2 , AstraZeneca
Quantum Leap Healthcare Collaborative (QLHC) announced that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL includes the study of olaparib and durvalumab, two agents from AstraZeneca.
Olaparib is a poly (ADP-ribose) polymerase (PARP) enzyme inhibitor and durvalumab is an anti-PD-L1 monoclonal antibody immunotherapy agent. Olaparib and durvalumab in combination with paclitaxel (chemotherapy) treatment will be compared to standard therapy (paclitaxel) alone in the new I-SPY 2 TRIAL treatment arm. Patients with HER2 negative breast cancer who are eligible to participate in the trial will be adaptively randomized into the olaparib/durvalumab/paclitaxel arm, another investigational arm, or standard of care (paclitaxel). Patients will then continue treatment with doxorubicin/cyclophosphamide (AC) regardless of assigned arm, all taking place in the neoadjuvant setting (treatment and/or chemotherapy prior to surgery).
The I-SPY 2 TRIAL, sponsored by QLHC, is a standing phase 2 randomized, controlled, multicenter study with an innovative Bayesian adaptive design aimed to rapidly screen and identify promising new treatments in specific subgroups of women with newly-diagnosed, high-risk (high likelihood of recurrence), locally-advanced breast cancer (Stage II/III).
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: